Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTubacin is a selective inhibitor of HDAC6; inhibits the second deacetylase domain (DD2). Does not inhibit HDAC6 histone deacetylase activity; reversibly inhibits α-tubulin deacetylation. Increases α-tubulin acetylation levels with no effect on histone acetylation or cell cycle progression.
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of Tubacin is reviewed on the Chemical Probes website.
分子量 | 721.86 |
公式 | C41H43N3O7S |
储存 | Store at -20°C |
纯度 | ≥96% (HPLC) |
CAS Number | 1350555-93-9 |
PubChem ID | 6675804 |
InChI Key | BHUZLJOUHMBZQY-YXQOSMAKSA-N |
Smiles | OCC(C=C4)=CC=[C@@]4[C@@H]1C[C@H](CSC2=NC(C6=CC=CC=C6)=C(C5=CC=CC=C5)O2)O[C@H]([C@]3=CC=C(NC(CCCCCCC(NO)=O)=O)C=C3)O1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 7.22 | 10 |
以下数据基于产品分子量 721.86。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 13.85 mL | 69.27 mL | 138.53 mL |
0.5 mM | 2.77 mL | 13.85 mL | 27.71 mL |
1 mM | 1.39 mL | 6.93 mL | 13.85 mL |
5 mM | 0.28 mL | 1.39 mL | 2.77 mL |
参考文献是支持产品生物活性的出版物。
Haggarty et al (2003) Multidimensional chemical genetic analysis of diversity-orientated synthesis-derived deacetylase inhibitors using cell-based assays. Chem.Biol. 10 383 PMID: 12770821
Haggarty et al (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc.Natl.Acad.Sci.USA 100 4389 PMID: 12677000
Jiang et al (2008) Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J.Neurosci. 28 12993 PMID: 19036992
If you know of a relevant reference for Tubacin, please let us know.
关键词: Tubacin, Tubacin supplier, Tubacin, HDAC, inhibitors, class, II, histone, deacetylase, inhibits, deacetylases, alpha-tubulin, α-tubulin, a-tubulin, acetylation, HDAC6, epigenetics, [537049-40-4], Class, HDACs, 3402, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Tubacin and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.